Breakthrough Regimen Reshapes Treatment Landscape for Muscle-Invasive Bladder Cancer

The FDA has cleared a landmark combination therapy for patients battling muscle-invasive bladder cancer—a particularly aggressive form of the disease where tumors penetrate the bladder muscle wall. This dual-drug approach pairs Merck’s immunotherapy KEYTRUDA with Padcev, an antibody-drug conjugate, marking the first and only regimen of its kind approved for this indication.

Understanding the Clinical Challenge

Bladder cancer severity escalates significantly when it becomes muscle-invasive. The condition often necessitates radical cystectomy (surgical removal of the bladder), yet approximately 50% of patients still face recurrence post-surgery. The real problem: many patients cannot tolerate cisplatin-based chemotherapy due to underlying health conditions, leaving them with surgery as the sole option. This approval addresses that critical gap.

What The Trial Results Show

The FDA decision rested on data from KEYNOTE-905, a phase 3 trial evaluating perioperative (around-surgery) administration of KEYTRUDA alone or paired with Padcev. The results were compelling:

• 60% reduction in event-free survival risks compared to surgery alone after 25.6 months of follow-up
• 50% improvement in overall survival outcomes
• 57.1% pathologic complete response rate versus just 8.6% with surgery alone

These figures represent a substantial shift in how physicians might manage this serious bladder cancer scenario going forward.

How The Drugs Work

KEYTRUDA (pembrolizumab) functions as a PD-1 checkpoint inhibitor administered intravenously. The newer formulation, KEYTRUDA QLEX—approved just this September—delivers the same active ingredient via subcutaneous injection as a fixed-dose combination with berahyaluronidase alfa, offering administration flexibility. Padcev, co-developed by Astellas and Seattle Genetics (now part of Pfizer), represents an antibody-drug conjugate specifically engineered for muscle-invasive and urothelial cancers.

Safety Considerations

Adverse reactions occurred in at least 20% of treated patients. Serious immune-mediated events including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis were documented—aligned with known PD-1 inhibitor safety profiles. These risks require careful patient selection and monitoring.

Market Impact And Stock Performance

For Merck shareholders, KEYTRUDA continues its dominant trajectory. Third-quarter 2025 sales reached $8.1 billion, representing 10% year-over-year growth. MRK has ranged from $73.31 to $105.07 over the past year, closing Friday at $97.76, up 2.94%.

This approval represents potential practice-changing medicine for a patient population previously limited to surgical intervention alone, establishing what could become the new standard of care for cisplatin-ineligible patients with muscle-invasive bladder cancer.